Cellectar Biosciences Inc(CLRB) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Cellectar BioSciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. The company is headquartered in Florham Park, New Jersey and currently employs 15 full-time employees. The firm is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The firm's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Current Price

$1.46

RSI

33.934

Beta:

1.730281

September 30, 2020
633.6K
-3.5M

-13.313 %
-0.207 %

$0
$0
$0
$0
$0
$0
%
%
%
0.000 %
0.000 %

$-14,092,912
$-13,239,027
$-13,562,290
$-6,180,326
$-5,495,030
$-8,106,395
-6.059 %
2.442 %
-54.430 %
-11.088 %
47.522 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.